Moesin Expression in Clear Cell Renal Cell Carcinoma

Completed

• Conditions: Renal Cell Carcinoma

• Registration Number: NCT06055660
• Lead Sponsor: Sohag University

Brief Summary

Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are several histological variants of RCC that are associated with variable prognostic outcomes. Epithelial-mesenchymal transition (EMT) is a phenomenon in which the epithelial cells acquire some mesenchymal criteria as enhanced invasive potential. There are several cell surface molecules that are implicated in EMT. Moesin is one of these molecules that is involved in EMT, which is associated with enhanced invasive potential and poor prognosis. Targeting Moesin by novel therapeutic agents may prevent EMT and improve prognosis of patients with RCC.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-01-01
• Primary Completion: 2021-10-31
• Study Completion: 2021-12-31
• Status Verified: 2023-09
• Study First Submitted: 2023-09-20
• Study First Submitted QC: 2023-09-20
• Last Update Submitted: 2023-09-20
• Study First Posted: 2023-09-28
• Last Update Posted: 2023-09-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. All cases of ccRCC.
2. Tissue blocks with material adequate for immunohistochemical evaluation.
3. All cases with accessible clinical data.

Exclusion Criteria

1. Cases of renal neoplasms other than ccRCC.
2. Patients who received preoperative chemotherapy or radiotherapy.
3. Patients with ccRCC who were diagnosed by tru-cut biopsies only and didn't undergo radical operations.
4. Cases with insufficient/destructed material.
5. Patients with inadequate clinical data.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Detection of Moesin in renal cell carcinoma	6 months	different levels of moesin expression will be correlated with some tumor characteristics as patients' ages, sexes, tumor site, tumor grades, stages and nodal statuses.